Cas:939756-02-2 1-[(3-chlorophenyl)methyl]indazol-5-amine manufacturer & supplier

We serve Chemical Name:1-[(3-chlorophenyl)methyl]indazol-5-amine CAS:939756-02-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-[(3-chlorophenyl)methyl]indazol-5-amine

Chemical Name:1-[(3-chlorophenyl)methyl]indazol-5-amine
CAS.NO:939756-02-2
Synonyms:1-(3-CHLOROBENZYL)-1H-INDAZOL-5-AMINE;1-(3-Chloro-benzyl)-1H-indazol-5-ylamine 3HCl salt
Molecular Formula:C14H12ClN3
Molecular Weight:257.71800
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:43.84000
Exact Mass:257.07200
LogP:3.90140

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1-(3-CHLOROBENZYL)-1H-INDAZOL-5-AMINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(3-Chloro-benzyl)-1H-indazol-5-ylamine 3HCl salt physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-(3-Chloro-benzyl)-1H-indazol-5-ylamine 3HCl salt Use and application,1-(3-Chloro-benzyl)-1H-indazol-5-ylamine 3HCl salt technical grade,usp/ep/jp grade.


Related News: The insulin-only and bihormonal configurations may be helpful in diabetes. 1-[(3-chlorophenyl)methyl]indazol-5-amine manufacturer Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers. 1-[(3-chlorophenyl)methyl]indazol-5-amine supplier The insulin-only and bihormonal configurations may be helpful in diabetes. 1-[(3-chlorophenyl)methyl]indazol-5-amine vendor In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available. 1-[(3-chlorophenyl)methyl]indazol-5-amine factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.